🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8 results for “gilteritinib” Clear

  1. GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  2. Gilteritinib

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  3. Vidaza 25 mg/ml powder for suspension for injection, Gilteritinib

    Astellas Pharma GmbH

    Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

    phase 3 small molecule active

    1 trial

  4. GVA + HDAC Consolidation & Gilteritinib Maintenance

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  5. Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Gilteritinib, ARA-cell® 40 mg Injektion 20 mg/ml Injektionslösung / Konzentrat zur Herstellung einer Infusionslösung, Gilteritinib, Bendarabin 50 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Citarabina Hikma 1 g/10mL Soluzione Iniettabile

    Astellas Pharma GmbH

    FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  6. A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC)

    Astellas Pharma GmbH

    Locally advanced or metastatic NSCLC

    phase 1 other active

    1 trial

  7. Gilteritinib

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia With FLT3/ITD Mutation

    phase 1 small molecule active

    1 trial

  8. Ivosidenib,Venetoclax,gilteritinib,Selinexor

    China SXT Pharmaceuticals

    AML

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources